StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

Aquestive Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Aquestive Therapeutics's enterprise value was $401.53M on Nov 11, 2026, against $624.00M a year earlier. Over the last 5 years it ranged from $11.89M to $656.85M, with a median of $216.91M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$401.53M-38.9%
2025Dec 31, 2025$656.85M+166.3%
2024Dec 31, 2024$246.70M+124.5%
2023Dec 29, 2023$109.90M+267.2%
2022Dec 30, 2022$29.93M-76.0%
2021Dec 31, 2021$124.76M-23.4%
2020Dec 31, 2020$162.80M+30.4%
2019Dec 31, 2019$124.84M+34.0%
2018Dec 31, 2018$93.15M–

More Aquestive Therapeutics figures

See a number that looks wrong?